Monday, April 4, 2011
Merck & Co. Inc., of Whitehouse Station, N.J., reported final results from a Phase III study of Victrelis (boceprevir), its oral protease inhibitor for hepatitis C virus (HCV), in combination with standard of care (SOC) peginterferon alfa-2a and ribavirin, with data showing that, over the 48-week treatment period, two-thirds (64 percent) of treatment-failed patients with HCV genotype 1 receiving the triple-drug therapy achieved sustained virologic response (SVR) vs. 21 percent receiving SOC alone.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.